Please assess the completion status of the following clinical trial:

Trial Title: Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 60 years;~* DSM-5 (Diagnostic and statistical manual-5) diagnosis of major depressive disorder, single or recurrent episode;~* Subjective cognitive decline, defined as endorsing 20% of items on the Cognitive Complaint Index (CCI);~* depression severity: MADRS (Montgomery-Asberg Depression Rating Scale) ≥ 15;~* cognition: MOCA (Montreal Cognitive Assessment) ≥ 24;~* fluent in English;~* intact hearing / vision allowing completion of study procedures;~* for individuals on antidepressants at study entry, they must be on a stable dose for at least 6 weeks.~Exclusion Criteria:~* Other Axis I psychiatric disorders, except for anxiety symptoms occurring in a depressive episode;~* History of alcohol or drug dependence or abuse in the last 3 years;~* Tobacco or nicotine use in last year;~* History of a developmental disorder or IQ score \< 70;~* Acute suicidality;~* Acute grief (\<1 month);~* Current or past psychosis;~* Primary neurological disorder, including dementia, stroke, brain tumors, etc.;~* Any MRI contraindication;~* Unstable medical illness;~* Allergy or hypersensitivity to nicotine patches;~* Regular use of drugs with centrally acting cholinergic or anticholinergic properties in last 4 weeks, including acetylcholinesterase inhibitors;~* Current or planned psychotherapy;~* Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in last two months.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transdermal nicotine patch (Type: EXPERIMENTAL): Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).